The drugmaker had planned to donate 607,000 vials of remdesivir — the drug that received FDA emergency approval for use in treating COVID-19 patients after it was shown to shorten recovery time in patients with the virus — in the next six weeks, but now plans to donate 940,000, according to a letter an HHS official sent to governors May 16.
Rep. Lloyd Doggett, D-Texas, gave a copy of the letter to STAT and said “there was no explanation of the change.”
In a May 18 call with leaders of physician and hospital groups, Robert Kadlec, MD, the HHS assistant secretary for preparedness and response, said HHS would receive the additional doses of remdesivir from Gilead in June, two people on the call told STAT.
The additional doses would be enough to treat 30,000 to 55,000 more COVID-19 patients.
HHS has been using data from hospitals to get an idea of where to distribute remdesivir, but this week’s request for data was canceled May 18, the day it was due. HHS said it didn’t need more data at the moment, but that it intends to ask for updated data in the next few weeks.
Read the full article here.
More articles on pharmacy:
32 of 40 drugs deemed critical for COVID-19 in short supply
Gilead strikes deal to manufacture remdesivir for 127 countries
How Civica Rx has responded to drug shortages caused by COVID-19
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
